Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Assets (2018 - 2026)

Immunovant filings provide 8 years of Assets readings, the most recent being $1.1 billion for Q4 2025.

  • Quarterly Assets rose 150.01% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 150.01% year-over-year, with the annual reading at $776.2 million for FY2025, 16.49% up from the prior year.
  • Assets hit $1.1 billion in Q4 2025 for Immunovant, up from $583.0 million in the prior quarter.
  • Across five years, Assets topped out at $1.1 billion in Q4 2025 and bottomed at $292.1 million in Q3 2023.
  • Average Assets over 5 years is $539.8 million, with a median of $515.6 million recorded in 2022.
  • The largest annual shift saw Assets soared 277.09% in 2021 before it crashed 40.83% in 2024.
  • Immunovant's Assets stood at $543.2 million in 2021, then fell by 16.01% to $456.2 million in 2022, then skyrocketed by 55.94% to $711.4 million in 2023, then crashed by 40.83% to $420.9 million in 2024, then skyrocketed by 150.01% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Assets are $1.1 billion (Q4 2025), $583.0 million (Q3 2025), and $661.4 million (Q2 2025).